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Abstract
Transgender includes patients at various stages of their journey. It is important that
providers care for transgender patients with a culturally sensitive approach, awareness, and
competent skill. There are new terms to learn. There may be mental health issues and/or
substance use issues. Hormone therapy can have an impact on a person’s health. As a primary
care provider, it is important to be alert to these potential issues, addressing the patient’s
individual needs. This paper discusses the transgender patient, outlining basic care and issues
that can arise in a primary care setting.
Keywords: transgender; hormone therapy; primary care
Background
Incidence
Transgender individuals come from a variety of backgrounds, races, religions, ethnic
groups, and socioeconomic statuses, with many having fully productive lives. The incidence of
transgender persons is difficult to estimate due to lack of uniform data collection, with a wide
range of estimates for both transfemale/male-to-female (MTF) and transmale/female-to-male
(FTM) (Roberts and Fantz, 2014). The incidence is most likely to be much higher as data does
not capture individuals who do not have a primary provider or may be obtaining their treatments
from unauthorized individuals. With the passing of the Affordable Care Act came provisions for
stronger data collection so it is hoped that more accurate data will be available in the near future.

Disparities
Transgender individuals face health disparities related to social stigma, discrimination,
and denial of human rights. This results in higher rates of HIV/STDs, victimization, substance
abuse, and psychiatric disorders (U.S. Department of Health and Human Services, 2015).
Transgender youth are more likely to be homeless and two to three times more likely to attempt
suicide (U.S. Dept. of Health and Human Services, 2015). Elderly transgender individuals have
additional barriers to healthcare due to isolation and lack of trained social services and providers.
Transgender people are also less likely to have health insurance (U.S. Dept. of Health and
Human Services, 2015).
Barriers to healthcare for the transgender person tend to center around four main issues:
the reluctance to disclose one’s identity, the lack of experienced providers and resources,
financial barriers, and structural barriers (Roberts and Fantz, 2014). Disclosure can range from
the difficulty communicating with the primary provider as well as others in the community, such
as pharmacist or laboratory technician (Redfern and Sinclair, 2014). Structural barriers include
lack of unisex restrooms, inpatient room assignment based on gender, accurate documentation in
electronic record and billing/coding systems, and appropriate reference ranges in laboratory
systems. Financial barriers include lack of insurance coverage for gender specific laboratory
testing, medications, and reassignment surgery. Some people have benefit limits of mental health
visits per year. Medical and nursing programs lack education related to the care of the
transgender patient, making the availability of quality, culturally competent care sparse. One of
the goals of Healthy People 2020 (2010) is to improve the health, safety, and wellbeing of
transgender individuals by providing culturally competent health care and improving education
of transgender patients in medical schools. (U.S. Department of Health and Human Services,

2015). This should include education and awareness by all health care providers, increasing the
number of providers capable of delivering competent care, and thus improving access to care.
Resources for the provider are included in table 1.
Considerations in Primary Care
Transgender defined
Gender dysphoria is recognized by the Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) as a mental health condition. (American Psychiatric Association, 2013).
There is new terminology specific to the transgender population (Gay Alliance, 2013; Alegria,
2011). Gender is often mistakenly referred to when identifying whether someone was born a
female or a male, a very distinct binary concept. What many people believe as gender is actually
sex, which is the biological assignment at birth, the physical attributes of a person. It is important
for the practitioner to not interchange these terms as they hold different meaning to different
individuals. Characteristics of Gender dysphoria, along with other terminology are described in
table 2.
Cultural Competency
As a provider, awareness of a person’s gender identity and biological sex is essential in
order to provide competent care and recommend appropriate care and measures for conditions
specific to this population (Holmes and Freeman, 2012). It is important for the provider to
address the patient with their preferred name and not document in their record with their
preferred name in quotation marks. The provider needs to understand the patient and desired
goals in order to provide patient-centered quality care and improved outcomes. Key elements of
culturally competent care include the following: being respectful--if you are not sure how

someone identifies, then it is proper to ask in a respectful way and in a private place; do not
assume that sex reassignment surgery is the goal for all transgender people; remember that
gender identity does not define sexual orientation; maintain privacy of all patients; and use
preferred name when referring to the past (Gay Alliance, n.d.).
Role of the NP
Nurse practitioners are essential components to the care of the transgender patient. Roles
include care coordination, creation of the shared care plan, and provision of primary care as well
as specialty care, depending upon the training and level of expertise of the practitioner. There is a
process, preferably called a “transition” that transgender individuals become involved with in
regards to their sexual identity. It is a very individualized process that is dictated by that person’s
choices. It may include hormone replacement therapy, counseling, and surgery. This process is to
facilitate congruency between the person’s internal and external expression. Hormonal therapy
aids in the physical expression of the desired gender. The counseling addresses the mental health
issues. The individual learns to cope with the stress that they encounter, both internally and
externally, in regards to their chosen gender identity. Surgery addresses the permanent physical
change that some individuals seek in order to live more congruently with their chosen gender
identity. Transmale patients may elect to undergo breast reduction or bilateral mastectomy, often
referred to as “top surgery”. They may also elect for a hysterectomy, salpingo-oophorectomy,
and phalloplasty. Transfemale patients may elect to undergo breast augmentation surgery using
implants or lipofilling. They may also elect to have an orchiectomy and vaginoplasty (Coleman,
et al, 2012).

Hormonal therapy
Hormone therapy can help to promote the outward or external appearance to be more in
line with what that individual feels. It can take an average three to six months to see any physical
effects from the hormones with maximum effects taking up to five years (Coleman, et al., 2012).
Patients must meet the criteria for hormone therapy prior to initiation. This includes the
diagnosis of persistent gender dysphoria, the capacity to make informed decisions and consent to
treatment, and if significant medical or mental health concerns are present, they must be wellcontrolled (Coleman, et al., 2012).
The purpose of hormonal treatment for FTM is to reduce female secondary sex
characteristics, including menses, and induce male secondary sex characteristics. It is important
to discuss with the patient that complete elimination of the natal sex characteristics is rare
(Steinle, 2011). Hormonal treatment for MTF is to reduce male secondary sex characteristics and
induce female secondary sex characteristics. This is done using the lowest effective dose that
will optimize desired effect and provide the lowest risk of side effects. Hormone therapy
including desired effects, risks or potential risks, and dosing is noted in table 3.
Hormone levels should be checked monthly until an appropriate dose is established. After
this, monitoring is required every three to four months for the first year, completing a directed
history and physical, ALT, fasting glucose and lipid panel, CBC, and trough hormone levels.
After one year, if stable, monitoring can move to every six to twelve months (Steinle, 2011).
Target for hormone therapy for FTM is to increase testosterone levels to that of a normal male
(300-1000 ng/dl). Target for hormone therapy for MTF is to decrease testosterone levels to that
of a normal female (30-100 ng/dl) without supra-physiological levels of estradiol (<200 pg/ml)
by administering estrogen and an antiandrogen, such as spironolactone (Gardner & Safer, 2013).

Screening is needed prior to the initiation of hormone treatment and this can be
accomplished by a primary care provider who is knowledgeable about protocols (Steinle, 2011).
First, a complete history and physical, including gynecological and psychological evaluations,
needs to be completed. Family history, particularly pertaining to reproductive cancers, early
atherosclerosis, hypertension, hyperlipidemia, and diabetes, needs to be ascertained. For women
who chose to have top surgery (double mastectomy), it is important to do a chest wall exam and
axillary lymph node exam if any breast tissue remain (Steinle, 2011). Lab tests that would be
prudent include fasting lipid panel, fasting glucose or HgBA1c, pregnancy test if sexually active
with natal man, liver and kidney functions, hormone levels (female—estradiol, testosterone,
prolactin, luteinizing hormone), Pap smear/HPV, STD screening, and sleep apnea evaluation.
Contraindications to testosterone treatment includes pregnancy, unstable coronary artery
disease, androgen-sensitive breast cancer, or active endometrial cancer. Possible
contraindications include cardiovascular disease, hyperlipidemia with cardiac complications,
cerebrovascular disease, thromboembolic disease, history of deep vein thrombosis,
polycythemia, severe obstructive sleep apnea, and active substance abuse (Steinle, 2011).
Contraindications to estrogen treatment include previous thrombotic events related to an
underlying hypercoagulable condition, history of estrogen-sensitive neoplasm, and end-stage
chronic liver disease (Coleman et al, 2012). Risks involved with hormone therapy are described
in table 3.
Responsibilities of hormone prescribing providers includes performing the initial
evaluation as noted previously, discussing with the patient the risks and benefits of the hormone
therapy including reproductive options, confirming the patient has the capacity to make informed
decisions, provide ongoing monitoring, communicate regularly with the patient’s health care

team as applicable, and if needed provide the patient with a written statement indicating that they
are currently under medical supervision and treatment that includes hormone therapy, should the
patient need this for legal authorities (Coleman, et al., 2012).
Special considerations
There are special considerations that need to be made due to medication choice, delivery
mode, and patient history. It is important to monitor patients every three months for the first year
of hormone therapy once the dose is stabilized, then again every six to twelve months. These
recommendations are summarized in table 4 to facilitate use in practice.
Cardiovascular. Blood pressure needs to be monitored as both estrogen and testosterone
may increase blood pressure, especially in the presence of risk factors. Hormone therapy can also
have an effect on the lipid panel (Coleman, et al, 2012).
FTM
Testosterone may decrease the HDL and can have variable effects on the LDL and
triglycerides (Holmes and Freeman, 2012). Administration by intramuscular injection may
worsen this, so transdermal would be preferred. Patients with underlying risk factors such as
PCOS and dyslipidemia are more likely to experience this. Testosterone can cause significant
weight gain (more than 10%), particularly in the abdomen (Holmes and Freeman, 2012).
MTF
Estrogen can increase triglycerides, cardiovascular events, and the risk of pancreatitis.
Different modes of administration will impact this risk, with transdermal decreasing the risk,
thus a better choice for those with a pre-existing lipid disorder (Coleman et al, 2012). Estrogen

can also increase the risk of cardiovascular events in patient over the age of 50 with underlying
risk factors. Additional progestin use can increase this risk further (Coleman et al, 2012).
Hematopoesis and Liver. Both estrogen and testosterone can cause transient elevation in
liver enzymes (Holmes and Freeman, 2012) but rarely hepatotoxicity (Coleman et al., 2012).
FTM
Testosterone therapy can cause erythrocytosis (hematocrit > 50%), though this is dose
dependent with a higher risk occurring with injections (44%) and less with transdermal
preparation (3-18%) (Coleman, et al., 2012). If FTM and taking spironolactone, it is important to
monitor the potassium level to prevent hyperkalemia (Garner and Safer, 2013).
MTF
Monitoring for venous thromboembolism (VTE) should be done as the risk is increased
in patients over the age of 40, smokers, sedentary and/or obese individuals, those with any
underlying predisposition, and those using additional third generation progestins (Coleman et al.,
2012). This risk is decreased if using the transdermal preparation of estradiol, thus transdermal is
recommended for patients that are a higher risk of VTE. Estrogen increases the risk of
cholelithiasis and subsequent cholecystectomy (Coleman et al., 2012).
Endocrine. It is important to monitor for diabetes in the setting of hormone therapy as
both estrogen and testosterone can produce an increased risk for diabetes.
MTF

Estrogen increases the risk of hyperprolactinemia in the first year of treatment and high
dose estrogen may promote clinical appearance of preexisting but clinically unapparent
prolactinoma (Coleman et al., 2012). It is important to monitor the prolactin level regularly.
Cancer.
MTF
An annual mammogram should be done in any patients age 50 or older who have
undergone at least 5 years of hormone treatment. It should also be completed on anyone with a
body mass index over 35, or one with known risk factors such as Klinefelter syndrome (Coleman
et all., 2012), and anyone with a positive family history (Phillips et al., 2014). Prostate cancer
screening should be conducted according to the guidelines if the prostate remains. (Coleman et
al., 2012).
FTM
An annual mammogram should be completed if they have had a reduction mammoplasty,
over 40 years of age at the time of surgery, or not had any top surgery (Coleman et al., 2012).
They should have a yearly chest wall/axillary exam if they had a bilateral mastectomy (Phillips
et al., 2014). Cervical cancer should be conducted according to guidelines if the cervix remains
(Coleman et al., 2012).
Psychological. Screening for mental health issues should occur with both MTF and FTM
patients. Screening should include depression, suicide, Post Traumatic Stress Disorder (PTSD),
and Eating disorders, anxiety (Coleman et al., 2012). Substance abuse screening should be
completed, though the potential for abuse is less likely in patients undergoing hormone therapy

as they are addressing the disconnect and not needing to self-medicate (Holmes and Freeman,
2012).
FTM
Testosterone treatment may increase the risk of hypomania, mania, or psychotic
symptoms in people who have a predisposition. This is a dose related response that typically
occurs with supraphysiologic blood levels (Coleman et al., 2012).
Musculoskeletal. Screening for osteoporosis should be done in both FTM and MTF
patients. A bone mineral density or DEXA scan should be done prior to the initiation of
testosterone therapy if the person is at risk for osteoporosis. Otherwise it is recommended to start
DEXA scans at age 60 or earlier if hormone levels are consistently low (Gardner and Safer,
2013).
FTM
Testosterone maintains or increases the bone mineral density prior to an oophorectomy
and in the first three years of treatment. There will be an increased risk of bone mineral density
loss after an oophorectomy if the testosterone treatment is interrupted or insufficient (Coleman et
al., 2012).
Skin, Hair, Nails.
FTM
Testosterone can contribute to acne and androgenic alopecia (Coleman et al., 2012). It is
important to educate the patient regarding good skin care.

Sexual. There is an increased risk of sexually transmitted diseases in the presence of high
risk behaviors as with any individual (Redfern & Sinclair, 2014). Fertility is impaired with
hormone therapy. Changes will occur in libido, with estrogen decreasing libido and testosterone
increasing libido. Estrogen will decrease nocturnal erections, with a variable impact on sexually
stimulated erections (Coleman et al., 2012).
Lab Interpretation. Interpreting values that have different reference ranges for males
and females can prove complicating for providers. Some tests have gender specific reference
ranges. Liver enzymes, lipid profiles, and cardiac markers are reported based on the indicated
sex of the patient. It is not clear when the patient is transgender (Roberts & Fantz, 2014). The NP
may consult with a transgender specialist to determine which range to follow and when in that
patient’s treatment course it should change.
Summary
There are many aspects of healthcare related to the transgender patient. There is a need
for culturally sensitive and competent care. Unfortunately, there is a lack of education regarding
care for the transgender patient in nursing and medical schools as well as a lack of resources
available for the practicing provider, leaving the transgender person with great disparity
regarding accessing quality care. There is new terminology and understanding of the transition
process, including hormone therapy and surgery. The practitioner must understand where
resources can be located as well as develop competence in ensuring thorough health care
maintenance issues for patients undergoing hormone therapy. By gaining this knowledge, the NP
can improve access to quality healthcare, improving outcomes through the provision of
competent, compassionate, culturally sensitive care. The NP is well trained to provide advocacy,

care coordination, and provision of healthcare. This will result in individualized quality patient
centered care, which should lead to an optimum state of health.
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Table 1: Resources regarding transgender care
A Provider's Introduction to Substance Abuse
Treatment for Lesbian, Gay, Bisexual, and
Transgender Individuals (SAMHSA)
Lesbian, Gay, Bisexual, and Transgender
Health
Center of Excellence for Transgender Health
National LGBT Health Education Center
Guidelines for care of Lesbian, Gay, Bisexual,
and Transgender patients
Advancing Effective Communication, Cultural
Competence, and Patient- and Family-Centered
Care for the Lesbian, Gay, Bisexual, and
Transgender (LGBT) Community

http://store.samhsa.gov/product/A-Provider-sIntroduction-to-Substance-Abuse-Treatment-forLesbian-Gay-Bisexual-and-TransgenderIndividuals/SMA12-4104
http://www.cdc.gov/lgbthealth/transgender.htm
http://transhealth.ucsf.edu/trans?page=home-00-00
http://www.lgbthealtheducation.org/training/learningmodules/
http://www.lgbthealtheducation.org/training/learningmodules/
http://www.jointcommission.org/lgbt/

Table 2: Definitions related to transgender

Gender Dysphoria

•

Genderqueer

A person who does not identify with either male or female. They may
identify with both, neither, or somewhere in between.

Transgender

Umbrella term that includes anyone whose self-identity, behavior, or
anatomy falls outside of societal norms and expectations
Person whose gender identity is not congruent with their biological sex.
They may or may not pursue treatment to bring congruency to their
gender identity.

marked incongruence between one’s experienced or expressed gender
and their assigned gender
• must be present for at least 6 months
• must be manifested by a strong desire to be the other gender or some
alternative gender that differs from their assigned gender.
• must also be associated with significant distress or impairment
regarding social, school, or other important areas of functioning
Gender
Range of characteristics of men and women/ masculinity and femininity
assigned by society.
Gender
Expression of masculinity or femininity by a person based on societal,
expression/Gender cultural, and individual expectations.
role
Gender identity
A person’s sexual identity with male, female, neither, or both.

Transsexual

Transmale

Individual who was born a female but identifies with male and MAY
have used hormonal and/or surgical treatment to become a male.

Transfemale:

Individual who was born a male but identifies with female and MAY
have used hormonal and/or surgical treatment to become a female.
Native American term that refers to someone who identifies with both
multiple genders.
The state of not being transgender; people who identify with the sex that
they were assigned at birth

Two Spirit
Cisgender

Source: (Gay Alliance, 2013, American Psychiatric Association, 2013).

Table 3: Hormone therapy--desired effects, risks, dosing
FTM
• Voice
deepening
• Clitoral
enlargement
• Facial/Body
hair growth
• Menses
cessation
• Breast tissue
atrophy
• Body fat
percentage
decrease
(compared to
muscle mass)

MTF
• Breast tissue
growth
• Erectile
function
decrease
• Testicular size
decrease
• Body fat
percentage
increase
(compared to
muscle mass)

Increased Risk:
Polycythemia
Weight gain
Acne
Androgenic alopecia
(balding)
Sleep apnea
Potential risk:
Hyperlipidemia
Potentiated psychiatric
disorders (in presence of risk
factors present)
CVD (in presence of risk
factors)
HTN (in presence of risk
factors)
HTN (in presence of risk
factors)
Type 2 DM
Elevated liver enzymes
Increased Risk:
Venous thromboembolic
disease
Gallstones
Elevated liver enzymes
Weight gain
Hypertriglyceridemia
CVD (in presence of risk
factors)
Potential risk:
HTN
Hyperprolactinemia or
prolactinoma
Type 2 DM

Oral

Parenteral

Transdermal

Anti-androgen

Testosterone
undecanoate
(only available
outside US)
Testosterone
enanthate or
cypionate
Testosterone
undecanoate
(only available
outside US)
Testosterone
1% gel
Testosterone
patch

Spironolactone

Cyproterone
acetate (only
available
outside US)
GnRH agonists

Oral Estrogen

Parenteral

Transdermal
Source: (Gardner & Safer, 2013, Coleman, et al., 2012)

Oral
conjugated
estrogens
Oral 17-beta
estradiol
Estradiol
valerate or
cypionate
Estradiol patch

160-240
mg/day

50-200
mg/week or
100-200
mg/2 weeks
1000 mg/12
weeks

2.5-10g/day
2.5-7.5
mg/day

100200mg/day
(up to 400
mg)
50-100
mg/day

3.75 mg
subcutaneous
monthly
2.5-7.5
mg/day
2-6 mg/day
5-20 mg
IM/2 weeks
or 2-10 mg
IM/week
0.1-0.4
mg/2X week

Table 4 Monitoring recommendations

Issue
BP

Lipids

MTF
Effect
Increase BP

Increase
Triglycerides,
increase risk
pancreatitis

Increased risk
CV events in
pts >50 with
underlying
risk factors,
particularly
with
additional
progestin
Potassium Increased risk
if taking
spironolacton
e
CV
Events

VTE

FTM
Effect
May increase
BP, especially
in setting of
risk factors
Decrease HDL,
variable effects
LDL,
Triglycerides

Recommendation
Monitor BP

Issue
BP

Use transdermal to
lessen effect
particularly if high
risk; monitor lipid
panel every 3-4
months 1st yr, then
every 6-12 mos

Lipids

Monitor for risk
factors, reduce as
is feasible

Weight
gain

Monitor potassium
level every 3-4
months 1st yr, then
every 6-12 mos

Erythrocyt Dose and mode
dependent
osis (Hct
(44% IM, 18%
>50%)
transdermal)

Risk
Monitor for VTE;
increased if
Use transdermal if
>40, smokers, high risk
sedentary,
obese,
underlying
thrombophilic
disorder,
additional 3rd
generation
progestin use

>10% weight
gain, mostly in
abdomen

Skin, Hair, Acne,
androgenic
Nails
alopecia

Recommendation
Monitor BP

IM may worsen; use
transdermal to lessen
effect, particularly if
high risk (PCOS,
dyslipidemia)
monitor lipid panel
every 3-4 months 1st
yr, then every 6-12
mos
Monitor weight gain;
encourage exercise

Use Transdermal to
decrease risk
Monitor CBC every 34 months 1st yr, then
every 6-12 mos
Patient counseling
regarding skin care

Transient
elevation
enzymes

Monitor ALT every 34 mo 1st yr, then every
6-12 mos

Fasting glucose
Endocrine
every 3-4 mos 1st
yr, then every 6-12
mos
Increase risk
Monitor Prolactin
of
level, trough
hyperprolacti hormone levels
nemia in 1st yr every 3-4 mos 1st
tx; high dose yr, then every 6-12
may promote mos
clinical
appearance
preexisting
but clinically
unapparent
mammograph Annual:
>50 Breast
y
with > 5 yrs tx;
cancer
BMI >35; + family
hx; known risk
factors (Klinefelter
syndrome)

Decrease
insulin
sensitivity

Fasting glucose every
3-4 mos 1st yr, then
every 6-12 mos

Hormone
levels

Monitor trough
hormone levels
monthly until optimal
dose attained, then
every 3-4 months 1st
yr, then every 6-12
mos

Prostate
Cancer

Prostate exam

Cervical
Cancer

Pap smear

Psych

Screening for
depression,
suicide,
PTSD, eating
disorders,
anxiety,
substance
abuse

Psych

Screening for
depression,
suicide, PTSD,
eating
disorders,
anxiety,
substance
abuse
May increase
risk
hypomanic,
manic, or

Liver

Endocrine

Hormone
levels

Breast
Cancer

Transient
elevation
enzymes;
increases risk
cholelithiasis
and
cholecystecto
my
Increase risk
of Type II
DM

Monitor ALT
every 3-4 mo 1st
yr, then every 6-12
mos

According to natal
guidelines if
prostate remains
All patients each
appointment

Liver

Mammography Annual: reduction
mammoplasty or no
surgery, preop > 40
age
Yearly chest wall
exam if bilat
mastectomy
According to natal
guidelines if cervix
remains
All patients each
appointment

Osteoporosis

DEXA Scan

Prior to initiation
Osteotx if risk factors;
porosis
Age 60 or earlier if
hormone levels
consistently low

psychotic sx if
predisposition,
though dose
dependent or if
supraphysiological
hormone levels
DEXA Scan
Prior to initiation tx if
risk factors; Age 60 or
earlier if hormone
levels consistently low
If oophorectomy,
increased risk if tx
interrupted or
insufficient
Increased risk
Screen for STD as
due to high
warranted
risk behaviors
Impaired
Use lowest possible
fertility
dose for optimal effect
Increased
Libido

Increased risk Screen for STD as STD
due to high
warranted
risk behaviors
Impaired
Use lowest
Sexual
Sexual
fertility
possible dose for
Health
Health
Decreased
optimal effect
Libido
Decrease
nocturnal
erections,
variable effect
on sexually
stimulated
erections
Source: (Coleman et al, 2012, Holmes and Freeman, 2012, Garner and Safer, 2013, Steinle, 2011,
Phillips, et.al, 2014, Redfern & Sinclair, 2014)
STD

